Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder

Bibliography

• Judd LL, Akiskal HS, Schettler PJ, The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59(6):530-7
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL, Strakowski SM, 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;155(5):646-52
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;11(1-2):123-31
   Google Scholar
• Perlis RH, Ostacher MJ, Patel JK, Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163(2):217-24
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Axelson DA, Enhancing outcomes in patients with bipolar disorder: results from the Bipolar Disorder Center for Pennsylvanians Study. Bipolar Disord 2009;11(4):382-90
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Shelton MD, Rapport DJ, Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord 2001;67(1-3):241-55
   PubMed Web of Science ®Google Scholar
• Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000;48(6):573-81
   PubMed Web of Science ®Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105(3):164-72
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL, Strakowski SM, Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996;57(7):292-7
   PubMed Web of Science ®Google Scholar
• Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48(12):1082-8
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, McElroy SL, Strakowski SM, Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997;33(1):87-91
   PubMedGoogle Scholar
• Colom F, Vieta E, Martinez-Aran A, Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61(8):549-55
   PubMedGoogle Scholar
• Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002;63(5):384-90
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Bauer MS, Kilbourne AM, Self-reported medication treatment adherence among veterans with bipolar disorder. Psychiatr Serv 2006;57(1):56-62
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002;159(11):1927-9
   PubMed Web of Science ®Google Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52(6):805-11
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Tacchi MJ, Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005;7(Suppl 5):24-31
   PubMedGoogle Scholar
• El-Mallakh RS. Medication adherence and the use of long-acting antipsychotics in bipolar disorder. J Psychiatr Pract 2007;13(2):79-85
   PubMedGoogle Scholar
• Esparon J, Kolloori J, Naylor GJ, Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986;148:723-5
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996;57(Suppl 9):49-52
   PubMedGoogle Scholar
• Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994;165(6):827-9
   PubMedGoogle Scholar
• Naylor GJ, Scott CR. Depot injections for affective disorders. Br J Psychiatry 1980;136:105
   PubMed Web of Science ®Google Scholar
• Ahlfors UG, Baastrup PC, Dencker SJ, Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr Scand 1981;64(3):226-37
   PubMed Web of Science ®Google Scholar
• White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8(2):119-22
   PubMed Web of Science ®Google Scholar
• Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol 1986;1(Suppl 1):53-62
   PubMedGoogle Scholar
• Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007;27(1):35-45
   PubMed Web of Science ®Google Scholar
• Elliott KJ, Lewis S, el-Mallakh RS, The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia. Ann Clin Psychiatry 1994;6(3):197-203
   PubMedGoogle Scholar
• Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008;9(9):1451-62
   PubMed Web of Science ®Google Scholar
• Bond DJ, Pratoomsri W, Yatham LN. Depot antipsychotic medications in bipolar disorder: a review of the literature. Acta Psychiatr Scand 2007;116(Suppl 434):3-16
   Google Scholar
• Available from: http://www.risperdalconsta.com/risperdalconsta/shared/pi/ risperdalconsta.pdf#zoom=100. [Last accessed 24 January 2010]
   Google Scholar
• Ramstack JGG, D'Hoore P. Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb® microsphere technology. Schizophr Res 2003;60:314
   Web of Science ®Google Scholar
• Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005;6(3):129-37
   PubMedGoogle Scholar
• Sajatovic M, Madhusoodanan S, Fuller MA, Risperidone for bipolar disorders. Expert Rev Neurother 2005;5(2):177-87
   PubMedGoogle Scholar
• Rainer MK. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat 2008;4(5):919-27
   PubMedGoogle Scholar
• Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 2009;9(1):9-31
   PubMed Web of Science ®Google Scholar
• Remington G, Mamo D, Labelle A, A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006;163(3):396-401
   PubMed Web of Science ®Google Scholar
• Nesvag R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006;114(1):21-6
   PubMed Web of Science ®Google Scholar
• Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70(1):91-100
   PubMed Web of Science ®Google Scholar
• Nordstrom AL, Farde L, Wiesel FA, Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33(4):227-35
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93
   PubMed Web of Science ®Google Scholar
• Han C, Lee MS, Pae CU, Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(6):1219-23
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Jarboe K, Bossie CA, Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005;20(4):213-21
   PubMed Web of Science ®Google Scholar
• Available from: http://www.risperdal.com/risperdal/shared/pi/risperdal.pdf. [Last accessed 24 January 2010]
   Google Scholar
• Lasser R, Bossie CA, Gharabawi G, Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004;83(2-3):263-75
   PubMed Web of Science ®Google Scholar
• Mohl A, Westlye K, Opjordsmoen S, Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005;19(5 Suppl):22-31
   PubMed Web of Science ®Google Scholar
• Quiroz JA, Yatham LN, Palumbo JM, Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar i disorder. Biol Psychiatry 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Macfadden W, Alphs L, Haskins JT, A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11(8):827-39
   PubMed Web of Science ®Google Scholar
• Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 2006;26(5):530-1
   PubMed Web of Science ®Google Scholar
• Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl 2007;(434):50-6
   PubMedGoogle Scholar
• Benabarre A, Castro P, Sanchez-Moreno J, Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder. Actas Esp Psiquiatr 2009;37(3):143-7
   PubMed Web of Science ®Google Scholar
• Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int Clin Psychopharmacol 2008;23(2):88-94
   PubMed Web of Science ®Google Scholar
• Vieta E, Nieto E, Autet A, A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry 2008;9(3):219-24
   PubMed Web of Science ®Google Scholar
• Braunig P, Sacchetti E, Medori R. Risperidone long-acting injectable for maintenance therapy in bipolar disorder: an open-label pilot study. Int J Pscyhiatry Clin Pract 2008;12(1):74-7
   PubMed Web of Science ®Google Scholar
• Drake RE, Gates C, Cotton PG, Whitaker A. Suicide among schizophrenics. Who is at risk? J Nerv Ment Dis 1984;172(10):613-7
   PubMed Web of Science ®Google Scholar
• Heila H, Isometsa ET, Henriksson MM, Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry 1999;60(3):200-8
   PubMed Web of Science ®Google Scholar
• Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003;12(5):423-4
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 2004;55(3):264-9
   PubMed Web of Science ®Google Scholar
• Pompili M, Serafini G, Del Casale A, Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk. Expert Rev Neurother 2009;9(7):985-1004
   PubMed Web of Science ®Google Scholar
• Gonzalez-Pinto A, Mosquera F, Alonso M, Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006;8(5 Pt 2):618-24
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Ostacher MJ, Calabrese JR, Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163(2):210-6
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Eerdekens M, Karcher K, Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64(10):1250-7
   PubMed Web of Science ®Google Scholar
• Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008;69(Suppl 5):9-15
   PubMedGoogle Scholar
• Salzman C, Jeste DV, Meyer RE, Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008;69(6):889-98
   PubMed Web of Science ®Google Scholar
• Fu IL, Boarati MA, Stravogiannis A, Wang YP. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series. J Clin Psychiatry 2009;70(4):604-6
   PubMed Web of Science ®Google Scholar
• Kemp DE, Canan F, Goldstein BI, McIntyre RS. Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther 2009;26(6):588-99
   PubMed Web of Science ®Google Scholar
• Moller HJ. Long-acting risperidone: focus on safety. Clin Ther 2006;28(5):633-51
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160(6):1125-32
   PubMed Web of Science ®Google Scholar
• Smulevich AB, Khanna S, Eerdekens M, Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005;15(1):75-84
   PubMed Web of Science ®Google Scholar
• Rendell JM, Gijsman HJ, Bauer MS, Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006;(1):CD004043
   Google Scholar
• Gao K, Kemp DE, Ganocy SJ, Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9
   PubMed Web of Science ®Google Scholar
• Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007;64(4):442-55
   PubMed Web of Science ®Google Scholar
• Kane JM, Fleischhacker WW, Hansen L, Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70(5):627-43
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Bossie CA, Zhu Y, An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res 2005;77(2-3):129-39
   PubMed Web of Science ®Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65(8):1084-9
   PubMed Web of Science ®Google Scholar
• Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19(4):241-9
   PubMed Web of Science ®Google Scholar
• Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005;8(3):427-38
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Hsu DJ, Rosenquist KJ, Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann Clin Psychiatry 2004;16(2):69-73
   PubMedGoogle Scholar
• Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23(4):328-35
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Czobor P, Volavka J, Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160(2):290-6
   PubMed Web of Science ®Google Scholar
• Meaney AM, Smith S, Howes OD, Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-8
   PubMed Web of Science ®Google Scholar
• O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;22(2 Suppl):70-5
   PubMedGoogle Scholar
• Shim JC, Shin JG, Kelly DL, Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164(9):1404-10
   PubMed Web of Science ®Google Scholar
• Tang J, Weiter JJ. Branch retinal artery occlusion after injection of a long-acting risperidone preparation. Ann Intern Med 2007;147(4):283-4
   PubMed Web of Science ®Google Scholar
• Pelizza L. Long-acting risperidone-induced periorbital edema. J Clin Psychopharmacol 2008;28(6):709-10
   PubMed Web of Science ®Google Scholar
• Vermeir M, Naessens I, Remmerie B, Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36(4):769-79
   PubMed Web of Science ®Google Scholar
• Weiss RD, Greenfield SF, Najavits LM, Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998;59(4):172-4
   PubMed Web of Science ®Google Scholar
• Sengul C, Kalkanci O, Simsek D, Herken H. Maintenance electroconvulsive therapy combined with long-acting risperidone in the treatment of resistant bipolar affective disorder. J ECT 2009;25(4):282-3
   PubMed Web of Science ®Google Scholar
• Available from: www.abilify.com/pdf/pi.aspx. [Last accessed 24 January 2010]
   Google Scholar
• Available from: http://pi.lilly.com/us/zyprexa-pi.pdf. [Last accessed 24 January 2010]
   Google Scholar
• Available from: http://www1.astrazeneca-us.com/pi/Seroquel.pdf. [Last accessed 24 January 2010]
   Google Scholar
• Available from: http://media.pfizer.com/files/products/uspi_geodon.pdf. [Last accessed 24 January 2010]
   Google Scholar